301301 川宁生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.3619.62518.84914.2897.499
总资产报酬率 ROA (%)1.0637.33013.5359.1634.146
投入资产回报率 ROIC (%)1.1838.16814.9299.9854.487

边际利润分析
销售毛利率 (%)23.55729.25136.38631.57424.798
营业利润率 (%)13.01520.73129.31023.24914.268
息税前利润/营业总收入 (%)13.90620.99429.93024.43415.983
净利润/营业总收入 (%)10.05216.64424.31919.50010.771

收益指标分析
经营活动净收益/利润总额(%)101.602103.225101.401105.081118.651
价值变动净收益/利润总额(%)-1.988-0.612-0.547-1.318-1.837
营业外收支净额/利润总额(%)-2.699-1.950-0.756-0.330-11.790

偿债能力分析
流动比率 (X)2.5692.4132.1281.5601.672
速动比率 (X)1.7591.5531.4390.8991.161
资产负债率 (%)20.99922.26024.98831.22040.229
带息债务/全部投入资本 (%)7.2846.80511.50621.56835.033
股东权益/带息债务 (%)1,192.4081,278.165719.585349.970184.124
股东权益/负债合计 (%)375.088348.135299.473219.900148.436
利息保障倍数 (X)11.27931.82135.64019.3744.964

营运能力分析
应收账款周转天数 (天)89.68776.90952.74660.66878.132
存货周转天数 (天)151.803156.655148.326166.893177.739